Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 44Lymphoma, Mantle-Cell 22Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma 9Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Recurrence 6Neoplasms 6Lymphoma, B-Cell 5Leukemia, B-Cell 5Bronchiolitis Obliterans Syndrome 5Multiple Myeloma 3Leukemia, Lymphoid 3Hematologic Diseases 3Graft vs Host Disease 3Burkitt Lymphoma 3Melanoma 2Leukemia, Prolymphocytic 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioblastoma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1

Interventions

luspatercept 2vactosertib 1ibrutinib 1fludarabine phosphate 1Taxes 1Rituximab 1Pluvicto 1Pharmacogenomic Testing 1Observation 1Lenalidomide 1Iron-Dextran Complex 1Holistic Health 1Gemcitabine 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1Ascorbic Acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × ibrutinib × 1 year × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡